GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyloris Pharmaceuticals SA (FRA:52U) » Definitions » Median PS Value

Hyloris Pharmaceuticals (FRA:52U) Median PS Value : €0.00 (As of Dec. 13, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Hyloris Pharmaceuticals Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Hyloris Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €0.074. Hyloris Pharmaceuticals's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is €0.00.

As of today (2024-12-13), Hyloris Pharmaceuticals's share price is €5.72. Hyloris Pharmaceuticals's Median PS Value is €0.00. Therefore, Hyloris Pharmaceuticals's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for Hyloris Pharmaceuticals's Median PS Value or its related term are showing as below:

FRA:52U's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.68
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

Hyloris Pharmaceuticals Median PS Value Historical Data

The historical data trend for Hyloris Pharmaceuticals's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyloris Pharmaceuticals Median PS Value Chart

Hyloris Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Median PS Value
Get a 7-Day Free Trial - - - - -

Hyloris Pharmaceuticals Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Hyloris Pharmaceuticals's Median PS Value

For the Biotechnology subindustry, Hyloris Pharmaceuticals's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hyloris Pharmaceuticals's Price-to-Median-PS-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hyloris Pharmaceuticals's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Hyloris Pharmaceuticals's Price-to-Median-PS-Value falls into.



Hyloris Pharmaceuticals Median PS Value Calculation

Hyloris Pharmaceuticals's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=0.074*0
=0.00

10-Year Median PS Ratio is 0.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Hyloris Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €0.074.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hyloris Pharmaceuticals  (FRA:52U) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Hyloris Pharmaceuticals's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=5.72/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hyloris Pharmaceuticals Median PS Value Related Terms

Thank you for viewing the detailed overview of Hyloris Pharmaceuticals's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Hyloris Pharmaceuticals Business Description

Traded in Other Exchanges
Address
Boulevard Patience et Beaujonc No. 3/1, Liege, BEL, 4000
Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans areas such as cardiovascular, other reformulations, and established markets (high-barrier generics). It has two early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, a non-opioid analgesic product for the treatment of pain with various other products in the pipeline. Its revenue is mainly generated in the United States.

Hyloris Pharmaceuticals Headlines

No Headlines